EP4009794A1 - Formulation antiparasitaire de spores et/ou de protéines de bacillus thuringiensis pour le traitement de parasites de la familledes caligidae chez les poissons - Google Patents

Formulation antiparasitaire de spores et/ou de protéines de bacillus thuringiensis pour le traitement de parasites de la familledes caligidae chez les poissons

Info

Publication number
EP4009794A1
EP4009794A1 EP20756975.7A EP20756975A EP4009794A1 EP 4009794 A1 EP4009794 A1 EP 4009794A1 EP 20756975 A EP20756975 A EP 20756975A EP 4009794 A1 EP4009794 A1 EP 4009794A1
Authority
EP
European Patent Office
Prior art keywords
spores
crylab
fish
caligus
aquaculture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20756975.7A
Other languages
German (de)
English (en)
Inventor
Deborah VARGAS
Ana María SANDINO
Claudia RIOSECO
Esteban ARENILLAS
Yazmín FUENTES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consorcio Tecnologico De Sanidad Acuicola S A
Consorcio Tecnologico De Sanidad Acuicola SA
Universidad de Santiago de Chile
Original Assignee
Consorcio Tecnologico De Sanidad Acuicola S A
Consorcio Tecnologico De Sanidad Acuicola SA
Universidad de Santiago de Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consorcio Tecnologico De Sanidad Acuicola S A, Consorcio Tecnologico De Sanidad Acuicola SA, Universidad de Santiago de Chile filed Critical Consorcio Tecnologico De Sanidad Acuicola S A
Publication of EP4009794A1 publication Critical patent/EP4009794A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/22—Bacillus
    • A01N63/23—B. thuringiensis

Definitions

  • the claimed invention relates to the aquaculture field. It describes the composition, formulation and preparation of an antiparasitic agent of biological origin, for the treatment of an infestation caused by parasites (sea lice) of the Caligidae family in fish.
  • the claimed invention relates to the preparation of an aquaculture antiparasitic product based on the use of Bacillus thuringiensis, particularly Bacillus thuringiensis spores and/or recombinant proteins, for the treatment of the infestation caused by parasites of the Caligidae family in aquaculture. It also refers to the preparation of a composition suitable for use in the treatment of the infestation caused by parasites of the Caligidae family in fish. In another embodiment, the claimed invention refers to the preparation of a formulation based on Bacillus thuringiensis spores and/or recombinant proteins, for the treatment of the infestation caused by parasites of the Caligidae family in fish.
  • the field of the invention includes a method of treatment against the infestation caused by Caligus, by administrating Bacillus thuringiensis spores and/or recombinant proteins to fish, which is possible to be administered through diverse routes, such as through feed, by injection or immersion bath.
  • the invention includes the development of a product of biological origin to be applied in fish, for controlling parasites of the Caligidae family, based on Bacillus thuringiensis spores combined with Cry recombinant proteins.
  • Copepods are the most common parasites in wild fish and farm fish.
  • the term "sea lice” is used to define the species of copepods belonging to the Caligidae family, which affect salmon farming worldwide, generating a parasitism called caligidosis (Johnson et ah, 2004).
  • the species mainly affecting salmonid farming centers belong to the genera Caligus rogercresseyi and Lepeophtheirus salmonis, in the Southern and Norther Hemisphere, respectively (Boxshall and Bravo 2000, Burka et al., 2012).
  • copepod families relevant as parasites in aquaculture belonging to the families Ergasilidae (15%) Lernaepodidae (8%), and Lernanothropidae (5%).
  • Caligidosis which is a disease caused by the copepods Caligus rogercresseyi and Lepeophtheirus salmonis, is a persistent problem in the aquaculture industry, having no concrete and effective solution to date.
  • this disease affects more than 90% of the salmon industry, especially in Chile and Norway.
  • SLRC Sea Lice Research Center
  • the main problems caused by this disease relate to delayed growth of the parasitized fish, increase in stress, and the susceptibility of fish to be attacked by other opportunistic pathogens (Johnson et ah, 2004).
  • the life cycle of L. salmonis consists of 5 phases.
  • the first phase has two planktonic stages, called nauplii I and II.
  • the second phase corresponds to the copepodite stage, which is the infesting phase of the parasite where a host fish must be found.
  • the following stages are developed: chalimus (I and II, fixed stages), preadult (I and II, mobile stages) and mature adults (Costello, 2006).
  • C. rogercresseyi is similar to the aforementioned life cycle of L. salmonis, and it is characterized by having eight development stages: 3 planktonic stages (free life stages), and 5 parasitic stages (stages attached to the host) (Gonzalez et ah, 2003).
  • the first three planktonic stages are named nauplius I, nauplius II, and copepodite.
  • the copepodite is the infesting stage that must attach to the fish to keep developing to become adult.
  • the parasite develops a frontal filament which allows it to puncture and feed from the mucus and the skin of the fish.
  • chalimus I, II, II and IV immobile parasitic stages attached to the fish are generated, called chalimus I, II, II and IV, which are finally differentiated in adult females and males.
  • antiparasitics administered orally, such as emamectin and ivermectin benzoate, the mechanism of action thereof consists in activating the glutamate-gated chloride channels in nerve cells and muscle cells, hyperpolarizing cells, causing death of the parasite due to flaccid paralysis.
  • antiparasitics administered orally such as emamectin and ivermectin benzoate
  • the mechanism of action thereof consists in activating the glutamate-gated chloride channels in nerve cells and muscle cells, hyperpolarizing cells, causing death of the parasite due to flaccid paralysis.
  • ivermectin is forbidden and several derivatives thereof were removed from the market because they had negative effects on the marine environment.
  • the oral antiparasitic products are currently administered during the first third of the productive cycle of salmonids, wherein the control for the rest of the fattening period is mainly supported by the use of drugs administered by immersion.
  • pyrethroid-based drugs such as deltamethrin and cypermethrin, which act by activating the voltage-gated sodium channels, increasing permeability of nerve cells to sodium, hyperpolarizing the cell and causing paralysis (Sordehmd, 2012).
  • H2O2 hydrogen peroxide
  • the chemical compound most used nowadays (years 2016 to 2019) is the organophosphate medicament azamethiphos, which penetrates into the cuticle of insects and acts by inhibiting the acetylcholinesterase activity, leading to the death of the insect.
  • the claimed invention discloses the development of a treatment of biological origin, innocuous to the environment, wherein its mechanism of action depends on several active compounds, without generating long term resistance, unlike the chemical treatments currently used.
  • a biological compound is biodegradable, having thus a low environmental impact and no lack period. Moreover, it generates low resistance, since it is composed of many active compounds and it is species -specific, preventing damage to other species in the environment.
  • An example of sea lice control of biological origin in salmons was described in the Northern Hemisphere, wherein in order to control Lepeophtheirus salmonis, the use of fish of the Labridae family was proposed, which feed on ectoparasites (Groner et ah, 2013). However, this type of fish cannot be used in salmonid cultures in Chile, as they inhabit temperate regions.
  • Bacillus thuringiensis (Bt) is one of the most used microorganisms in control of biological origin. Mainly, this bacterium has been used for controlling insect populations affecting agricultural crops and for controlling insects transmitting diseases, such as dengue and malaria (Bravo, A. et ah, 2013).
  • B. thuringiensis is an anaerobic, facultative and chemoorganotrophic Gram-positive bacterium, which forms spores with entomopathogenic properties. Bt has been used as bio -controller, because during the sporulation stage it produces an inclusion of parasporal crystal proteins with insecticidal activity. There are hundreds of Bt subspecies producing, mainly during sporulation, one or more parasporal inclusions, each composed of one or several related insecticidal proteins thousands of gene sequences have been identified, corresponding to Cry proteins in different strains of B. thuringiensis, being classified in terms of the identity of their primary sequence into 74 groups of Cry proteins.
  • delta-endotoxins which have a varied genetic identity: crylA(a), crylA(b), crylA(c), crylB, crylC, crylD, cry2A, cry2B, cry3A, cry4A, cry4B, cry4C, cry4D, CytA.
  • Bt also produces other proteins, such as a-endotoxins, b- endotoxins, hemolysins, phospholipases, and chitinases (Soberon el al, 2010; Schiinemann el al, 2014).
  • the parasporal crystals of B. thuringiensis can be composed of more than five different proteins, depending on the strain.
  • these proteins can have activity against different groups of insects belonging to the orders lepidoptera, diptera, coleoptera, hymenoptera, hemiptera, isoptera, orthoptera, siphonoptera, thysanoptera, and activity has even been seen against some nematodes and gastropods.
  • the main factor for the activity of these proteins as endotoxins is the characteristic basic pH of the intestine of these insects, which allows the crystals to solubilize.
  • proteases specific to the intestine of each insect make cuts on the different Cry proteins, allowing the formation of the activated toxin, capable of binding to receptors located on the apical membrane of the intestinal epithelium. All these factors define the range of species that can affect a Cry protein and are related to the specificity of action of each toxin.
  • the parasporal protein of B. thuringiensis when ingested by the insect, is activated and interacts with the midgut epithelium of the larvae, causing a disorganization of membrane permeability, which causes the death of the insect (Soberon et al, 2010; Schiinemann el al, 2014).
  • Bt spore suspensions or inclusions have been commercially used for several decades in agriculture and it comprises spraying spores at frequent intervals in order to maintain an effective level of the biopesticide protein.
  • Most of the commercially available formulations are based on mixtures of parasporal crystals belonging to B. thuringiensis subsp. kurstaki (Btk) being effective against different pest species, and it is generally used against young lepidopteran larvae.
  • Bt formulations with different strains of significant commercial interest such as: HD-1, SA-11, SA- 12, PB 54, ABTS-351 and EG2348 (Riui etal, 2015).
  • the claimed invention demonstrates that a formulation or composition of spores and Cry proteins belonging to B. thuringiensis, each separately or in combination is capable of controlling the Caligus infestation in aquaculture.
  • the invention relates to the use of B. thuringiensis spores and proteins for preparing an antiparasitic composition or formulation for controlling Caligus.
  • the invention encompasses a method for controlling Caligus in aquaculture, which comprises administering to fish spores or products thereof belonging to B. thuringiensis for the control of the Caligus infestation.
  • document AU588849 B2 describes a method for controlling lice using a composition derived from Bacillus.
  • the lice treated are from sheep, cattle or other animals, and the examples verify the action of sporulated Bacillus in sheep lice.
  • document W02006096905 proposes the use of a bacterium of the genus Bacillus or a combination of cells and cellular components in the manufacture of a medicine for the treatment and prevention of sucking lice infestations in a patient, said medicine being administered to the hair or plumage of a mammal or bird.
  • lice are of the order Phthiraptera and of the family Pediculidae
  • Bacillus is of the thuringiensis species.
  • composition for killing human lice and/or their eggs which comprises a bacterium of the genus Bacillus or a combination of cells and a carrier for topical application.
  • This document proposes the treatment of human, animal or bird lice with B. thuringiensis and not the treatment in an aquatic environment of lice of the Caligidae family that infect fish. It should be noted that the examples in W02006096905 have no experimental evidence to support the method claimed in the present invention.
  • US5273746 discloses a method of controlling chewing lice of the order Phthiraptera , wherein said method comprises administering an effective amount of a B. thuringiensis toxin to a host harboring lice, or directly onto said lice.
  • the strain is selected from the group consisting of B. thuringiensis PS192N1, PS36A (NRRL B-18929), PS71M3, PS81F, PS92J, PS86A1, PS204G6, PS81I, PS81GG, PS201T6, PS84C3, PS211B2, PS91C2 (NRRL B-18931), PS40D1, and PS192M4.
  • This document describes that the strains of B. thuringiensis are safe for use in urban areas, and can be used in aquatic environments without damaging other species; however, it proposes the treatment of lice of the order Phthiraptera , instead of the lice present in an aquatic environment of the order Siphonostomatoida, to which the Caligidae family belongs, which infect fish.
  • US5273746 provides experimental evidence demonstrating the insecticidal capacity of a preparation with B. thuringiensis for sheep lice.
  • Document CN104397034 A refers to an eco-friendly pesticide, the composition of which contains veratridine, matrine, sodium laurate, cheletryne, surfactant, ethanol and Bacillus thuringensis (Bt), with a broad insecticidal spectrum for application in aquaculture.
  • the document describes that 3- 4 parts of Bt diluted 20-30 times are used in the insecticide.
  • the composition contains a mixture that is different from the one proposed in the claimed invention, indicating that its use is insecticidal and not to combat sea lice.
  • WO2012149549 A2 discloses microbiocidal compositions based on Bacillus strains that are administered by feeding with the capacity to control bacterial infections in aquaculture (farmed fish or crustaceans). Although this document describes in its specification that the strain may be Bt, its use is to control bacterial infections in aquaculture and not to combat sea lice. Nor does it indicate the use of a composition such as the one disclosed in the present application.
  • Document JP2005154405 A discloses the use of Bacillus thuringiensis to control fungi in farmed fish or crustaceans, especially Fusarium solani. As described in the document, the aim is to control fungi and not sea lice in salmonids. Nor does it indicate the use of a composition such as that described in the present application.
  • the claimed invention aims to solve the problem of controlling parasites of the Caligidae family, which affects salmon farming worldwide, providing an environmentally friendly solution, based on the treatment of biological origin, to the absence of effective treatments in the control of this parasitic infestation.
  • neurotoxic chemical compounds such as emamectin benzoate, pyrethroids and organophosphate compounds (azamethyphos), which damage the environment.
  • sea lice Caligus
  • the claimed invention proposes using a formulation based on Bacillus thuringiensis spores in combination with recombinant Cry proteins (recombinant endotoxins), which does not damage the environment.
  • biocontrol products based on this bacterium do not produce long-term resistance because their action is through several components, not only an active compound.
  • the product developed in the claimed invention is applied to seawater for the treatment of salmons by immersion baths or by injection or orally.
  • An advantage of the claimed invention is that the Bt-based product developed is active against larval (copepodites) and adult Caligus, while the current chemical treatments available in the industry only cause mortality of adult Caligus. This occurs because said treatments usually affect the nervous system of the parasites, which is not developed in larvae. With the antiparasitic composition developed, based on a combination of B. thuringiensis spores and recombinant Cry proteins of the same bacterium, 100% mortality of adult and copepodite Caligus.
  • Figure 1 Graph showing the survival of copepodites against different doses of Bt spores. It exhibits the survival curves of copepodites treated with different concentrations of spores from the strains ABTS-351, SA-11, and a mixture of Chilean native strains (N1-N2-N3). The resulting mortality was plotted after 240 min of treatment.
  • Figure 2 Graph showing the survival of adult Caligus rogercresseyi treated with spores of Bacillus thuringiensis subsp. Kurstaki strains ABTS-351 and ATCC-33679. It exhibits the survival percentage of adult Caligus treated with 2xl0 9 CFU/mL spores of Bt.
  • Figure 3 Graph showing the survival of adult C. rogercresseyi treated with Bt ABTS-351 spores produced in bioreactor. It exhibits the survival percentage of adult parasites treated with spores at a dose of 2xl0 8 CFU/mL in in vitro assays.
  • Figure 4 Graph showing the survival of copepodites treated with Bt ABTS-351 spores produced in bioreactor. The graph exhibits the survival percentage of larvae treated with Bt spores at a dose of 2.8x10 s CFU/mL in in vitro assays.
  • Figure 5 SDS-polyacrylamide gel electrophoresis 10% of the moieties of protein CrylAb expressed in E.
  • FIG. 6 SDS-polyacrylamide gel electrophoresis 10% of the moieties of protein CrylAb, produced in H. polymorpha and collected by Ni-NTA agarose affinity chromatography.
  • M represents the molecular size marker AccuRuler RGB Plus (Maestrogen)
  • ft corresponds to flowthrough (unretained flow in the column)
  • L is the resin wash control. Moieties eluted with 50 mM of imidazole (1-1 to 1-3) and 300 mM of imidazole (2-1 to 2-3) are observed.
  • Figure 7 Survival curve of C. rogercresseyi larvae treated with proteins Cryl, Cry2 and Cry3. The survival curve is observed when copepodites are treated with 300 pg/mL of each Cry protein.
  • U/T corresponds to the untreated control
  • B/C corresponds to the buffer control
  • proteins CrylAb, Cry2 and Cry3 are shown in the figure with their respective names.
  • FIG. 8 C. rogercresseyi larvae treated with Cry proteins. The images were taken with an optical microscope with a lOx objective.
  • A shows an untreated larva, which has only had contact with seawater.
  • B shows a larva treated with the CrylAb protein (300 pg/mL)
  • C shows a larva treated with a Cryl/Cry2 combination (300 pg/mL)
  • the arrows represent the presence of bubble- shaped structures.
  • FIG. 9 Survival curve of C. rogercresseyi adults treated with proteins Cryl, Cry2 and Cry3. The survival curve with a dose of 300 pg/mL of proteins Cryl, 2 and 3 is observed.
  • U/T corresponds to the untreated control
  • B/C corresponds to the buffer control
  • proteins Cry lAb, Cry2 and Cry 3 are shown with their respective names.
  • FIG. 10 Survival curve of C. rogercresseyi adults treated with proteins Cryl and Cry4. The survival curve with a dose of 300 pg/mL of each Cry protein. U/T corresponds to the untreated control, and the Cry proteins are indicated with their respective names.
  • FIG. 11 C. rogercresseyi female adults treated with 300 pg/mL of protein Cryl.
  • A shows an untreated ovigerous female observed with the stereoscopic lens, wherein the white square corresponds to the intestinal-anal area.
  • B corresponds to a lOx zoom with an optical microscope of the intestinal-anal area of an ovigerous female.
  • C ovigerous sacs of a female treated with the CrylAb protein 300 pg/mL are observed with a xlO zoom,
  • FIG. 12 Comparison of the in vitro antiparasitic activity of recombinant Cryl proteins.
  • A shows the survival curve of C. rogercresseyi adults treated with 150 pg/mL of CrylAb proteins expressed in E. coli BL21, as compared to CrylAb expressed in H. polymorpha.
  • B shows the survival curve of C. rogercresseyi adults treated with 150 pg/mL of proteins CrylAb and CrylAc both produced in E. coli BL21.
  • Figure 13 Survival curve of C. rogercresseyi larvae treated with a combination of proteins
  • FIG. 14 Survival curve of C. rogercresseyi adults treated with a combination of proteins Cryl and Cry4.
  • the survival curve of adult Caligus treated with a Cryl/Cry4 combination at a dose of 150 pg/mL of each protein for 360 minutes is shown.
  • U/T corresponds to the untreated control, and the Cry proteins are indicated with their respective names.
  • FIG. 15 Survival curve of Caligus rogercresseyi adults, treated with B. thuringiensis spores, supplemented with the CrylAb protein produced in E. coli. The survival percentage of adult parasites treated with lxlO 8 CFU/mL of spores obtained in reactor, combined with recombinant CrylAb in different amounts is shown.
  • FIG. 16 Survival curve of Caligus rogercresseyi larvae treated with B. thuringiensis spores combined with the CrylAb protein produced in E. coli. The survival percentage of copepodites treated with lxlO 8 CFU/mL of spores obtained in bioreactor in different amounts of recombinant CrylAb protein is shown.
  • FIG. 17 Survival curve of C. rogercresseyi adults treated with B. thuringensis spores combined with the CrylAb protein produced in H. polymorpha.
  • the survival curves of Caligus adults treated with lxlO 8 CFU/mL of Bt spores obtained in bioreactor supplemented with the CrylAb protein expressed and purified from H. polymorpha is shown.
  • Figure 18. Comparison of the effect of Bt spores on Caligus adults in in vivo and in vitro assays.
  • (A) shows the attachment percentage of Caligus adults per fish after an immersion treatment of 60 min with Bt ABTS-351 spores ⁇ in vivo).
  • U/T corresponds to the control of fish that received immersion treatment without the antiparasitic. 100% corresponds to the parasitic load of fish before the immersion treatment.
  • B shows the survival percentage of Caligus adults treated with spores at a dose of lxlO 8 CFU/mL in vitro. The untreated control corresponds to Caligus kept in Petri dishes with seawater.
  • Figure 19 Comparison of the effect of the combination of Bacillus thuringiensis spores and a protein extract containing CrylAb, on the survival of Caligus in in vivo and in vitro assays.
  • (A) shows the survival percentage of attached Caligus per fish, after the treatment of parasitized fish with Bt spores at a dose of lxlO 9 CFU/mL combined with CrylAb produced in H. polymorpha, without purification (420 pg/mL protein extract) (in vivo). 100% corresponds to the parasitic mean load of fish before the immersion treatment and the untreated control corresponds to fish subjected to a bath without antiparasitic compounds.
  • (B) shows the survival percentage of Caligus adults treated with Bt spores supplemented with CrylAb without purification, in vitro. The untreated control corresponds to Caligus kept in Petri dishes with seawater.
  • FIG 20 Effect of CrylAb injection on caligus survival in in vivo assays. It shows the percentage of caligus attached to the fish after injection treatment with CrylAb purified from E. coli. The untreated control corresponds to fish injected with physiological serum. 100% corresponds to the number of caligus attached to the fish before the injection (counting prior to the treatment for each condition).
  • Figure 21 Gradual evolution of the effect of Bt spores and CrylAb protein on adult L. salmonis, in vitro.
  • A Control group. It shows no effect on activity for control sea lice (without treatment).
  • B Bt Spores. Development of inactivity for adult after continuous exposure to Bt Spore (10 9 CFU/ml) over a period of 360 minutes after initial exposure.
  • Figure 22 Gradual evolution of the effect of Bt spores and CrylAb protein on L. salmonis copepodites, in vitro. It shows the gradual evolution of mortality or effect on L. salmonis untreated control group (A) and a group treated with Bt spores and CrylAb at 150 pg/ml (B) indicated according to the score: 0, 1, 2 and 3, wherein 0 - no effect; 1 - reduced movement; 2 - reduced movement and copepodites at the center of the wells; 3 - no movement.
  • the claimed invention relates to the development of an aquaculture antiparasitic composition or formulation based on a combination of Bacillus thuringiensis spores and recombinant Cry proteins of the same bacterium, as well as Bacillus thuringiensis spores and recombinant Cry proteins on their own, for the control of sea lice of the Caligidae family, through the treatment of infested fish by immersion baths, by injection or orally.
  • the infested fish may belong to the families Salmonidae, Eleginopsidae, Atherinopsidae, Paralichthyidae, or Cichlidae.
  • the Salmonidae family fish may be of the genus Salmo or Oncorhynchus . More particularly, said fish may be of the species Salmo salar and/or Oncorhynchus mykiss and/or Oncorhynchus kisutch, commonly called Atlantic salmon, rainbow trout, or coho salmon, respectively.
  • Eleginops maclovinus species commonly called rock cod
  • Basilichthys australis species commonly called silverside
  • Paralichthys adspersus species commonly called dover sole
  • Oreochromis aureus species commonly called tilapia
  • the Caligus (or caligus) parasite mentioned in the claimed invention belongs to the Caligidae family and it may belong to the genera Caligus and Lepeophtheirus, particularly it may belong to the Caligus rogercresseyi, Lepeophtheirus salmonis species, among other species.
  • composition or formulation according to the claimed invention has been developed to be acceptable for veterinary use.
  • the culture and sporulation conditions of Bt were characterized and standardized. Then, the antiparasitic activity of Bt on Caligus was assessed. The obtained results showed that Bt spores have antiparasitic activity against Caligus adults and larvae, in in vitro assays, producing in both cases 100% mortality in 180 minutes of treatment, while by 60 minutes of treatment a 50% mortality is reached for adult caligus, and more than 60% mortality for larvae. Moreover, it was demonstrated that the combination of spores and Cry proteins produces more than 70% mortality of adult and larval caligus in 30 minutes of treatment, and 100% mortality is reached in 90 minutes. In vivo assays demonstrated that the combination of spores and CrylAb reduces the parasitic load of the caligus infested fish, observing a similar effect to the one obtained in in vitro assays.
  • the spores in the claimed invention come from the bacterium B. thuringiensis subspecies kurstaki strains ABTS-351 and ATCC-33679.
  • the culture medium used contains Peptone lOgr/Lt, NaCl 5gr/Lt, Glucose 34gr/Lt, yeast extract 20gr/Lt, MnCh 20mg/L, ZnCh 40mg/L. It was seeded with 20% pre-inoculum and incubated for 8 days at 28°C. Obtaining Cry proteins
  • the antiparasitic activity of some Cry proteins in Caligus was assessed.
  • encoding gene sequences were selected from the following Cry proteins based on the information available in the literature and in the NCBI (National Center for Biotechnology Information) Pubmed site available in the Internet (ncbi.nlm.hih.gov/pubmed): CrylAb (GenBank: AY319967.1), CrylAc (GenBank: AD064600.1), Cry2 (GenBank: AM490199.1), Cry3 (Lambert y cols., 1992), and Cry4 (GenBank: ACR43758.2).
  • Cryl CrylAb, CrylAc
  • Cry2 Cry2Ad
  • Cry3, and Cry4 were cloned in different expression systems.
  • a modality of the expression system for these proteins can be prokaryotic, such as Escherichia coli or Bacillus subtilis
  • other modality of the expression system can be eukaryotic, such as Hansenula polymorpha or Trichoderma asperellium.
  • the recombinant proteins were purified and their caligus killing activity was assessed.
  • Table I Identification of encoding DNA sequences and recombinant Cry proteins used in the claimed invention. Once the Cry proteins were purified, their antiparasitic effect was determined. The results showed that the CrylAb protein at a dose of 300 pg/mL causes about 30% mortality of copepodites and adults after 60 minutes of treatment, reaching 100% mortality after 120 minutes of in vitro treatment. Proteins Cry2 and Cry4, at a dose of 300 pg/mL, are also active against Caligus, but with greater action times. 100% mortality of adult caligus is reached in 240 minutes of treatment with Cry2, and 90% mortality of adult caligus treated with Cry4 up to 360 minutes.
  • Cry3 is inactive at a dose of 300 pg/mL, since the parasites treated with this protein remain viable, like the untreated control, suggesting thus that the action of Cryl, Cry2, and Cry4 against Caligus is specific.
  • treatment assays were performed for C. rogercresseyi larvae with combinations of Cry proteins at a ratio of 1:1. The combinations used were Cryl/Cry3 and Cryl/Cry2, at a dose of 300 pg/mL each and Cryl/Cry4 at a dose of 150 mg/mL each.
  • the assays showed that the Cryl/Cry2 combination is the most effective, since with Cryl/Cry2 at a dose of 300 pg/mL each, a larval mortality is reached near to the sum of the effects of both proteins separately.
  • using a combination of 150 pg/mL of Cryl/Cry4 proteins allows reaching a slight increase in mortality of adult caligus over the mortality reached by each of the proteins separately.
  • the Cryl/Cry3 combination does not evidence an increase in the effect observed for each of the proteins on their own.
  • a combination of spores with recombinant Cry protein was tested.
  • Larvae and adults of Caligus were treated in vitro with a composition or formulation of Bt spores at a concentration of lxlO 8 CFU/mL together with a CrylAb protein at different concentrations (25, 50, 100 and 150 pg/mL, respectively).
  • a composition or formulation of Bt spores at a concentration of lxlO 8 CFU/mL together with a CrylAb protein at different concentrations (25, 50, 100 and 150 pg/mL, respectively).
  • the combination of spores and CrylAb protein at a dose of 150 pg/mL causes more than 70% mortality of adult caligus in 30 minutes of treatment, and 100% mortality is reached by 90 minutes.
  • the combination of spores with CrylAb at a concentration of 150 pg/mL have a better effect, reaching about 80% mortality in 30 minutes and 100% mortality in 90 minutes.
  • the combination of spores at a concentration of lxlO 8 CFU/mL with increasing concentrations of CrylAb, from 25 pg/mL to 150 pg/mL cause an incremental increase in mortality of C. rogercresseyi.
  • Another embodiment of the claimed invention corresponds to assays with a combination of Cry protein and different doses of spores, which showed that using a dose of lxl0 6 CFU/mL to lxlO 9 CFU/mL combined with 150 ug/mL of CrylAb results in 75% to 100% mortality of caligus in 300 minutes of in vitro treatment.
  • the first test consisted in the treatment by immersion with Bt spores.
  • fish from the Salmo salar species infested with Caligus rogercresseyi were used, which were treated for 60 minutes with B. thuringiensis spores of the strain ABTS-351 obtained in bioreactor, reaching 27% mortality, similar to the percentage achieved with the same dose of these spores in in vitro assays.
  • an assay was performed, which consisted in the treatment by immersion of S. salar fish parasitized with a high load of C. rogercresseyi , to assess the antiparasitic effect of Bt spores of the strain ABTS-351 obtained in bioreactor, supplemented with a protein extract containing CrylAb.
  • the fish were treated for 60 minutes with the composition of spores combined with the unpurified CrylAb protein, reaching 38% mortality. This result is also similar to the one observed in vitro.
  • the invention relates to an aquaculture parasiticidal composition or formulation, comprising at least one of: a) spores of Bacillus thuringiensis subsp. Kurstaki strain ABTS-351, and/or ATCC-33679; and/or b) one or more recombinant proteins selected from CrylAb, Cry 1 Ac, Cry 2 and Cry 4.
  • the claimed invention in an additional aspect, refers to an aquaculture parasiticidal composition or formulation as described above, comprising one or more recombinant proteins selected from CrylAb, Cry 1 Ac, Cry 2 and Cry 4.
  • the aquaculture parasiticidal composition or formulation comprises spores of a Bt strain var. Kurstaki ABTS-351 and/or ATCC-33679; and one or more recombinant proteins selected from CrylAb, Cry 1 Ac, Cry2 and Cry4.
  • the aquaculture parasiticidal composition or formulation as described above comprises the recombinant protein CrylAb (SEQ ID NO: 2).
  • the aquaculture parasiticidal composition or formulation as described above comprises the recombinant protein CrylAc (SEQ ID NO: 4).
  • the aquaculture parasiticidal composition or formulation as described above comprises the recombinant protein Cry2 (SEQ ID NO: 6).
  • the aquaculture parasiticidal composition or formulation as described above comprises the recombinant protein Cry4 (SEQ ID NO: 8).
  • the aquaculture parasiticidal composition or formulation as described above comprises spores of a Bt strain var. Kurstaki ABTS-351 and/or ATCC-33679.
  • the claimed invention refers to an aquaculture parasiticidal composition or formulation as described above, wherein the spores are present in a range between lxlO 6 and lxlO 10 CFU/mL.
  • the aquaculture parasiticidal composition or formulation as described above comprises the recombinant protein in a range between 25 and 300 pg/mL.
  • a veterinary aquaculture parasiticidal composition or formulation which comprises the aquaculture parasiticidal composition or formulation as described above, and a veterinarily acceptable carrier, selected from maltodextrin, sucrose, sorbitol and/or gelatinized corn starch.
  • a preferred embodiment of the claimed invention relates to a veterinary aquaculture parasiticidal composition or formulation as described in the preceding paragraph, wherein the composition is present in a form selected from the group consisting of immersion bath, injectable formulation, or feed formula.
  • the claimed invention also refers to the use of a veterinary aquaculture parasiticidal composition or formulation as described above, for preparing a veterinary medicament useful for treating fish infested with the sea lice parasite, wherein the sea lice belongs to the genera Caligus and Lepeophtheirus.
  • the claimed invention refers to the use of a veterinary aquaculture parasiticidal composition or formulation for preparing a veterinary medicament useful for treating fish infested with the sea lice parasite, wherein the sea lice belongs to the genera Caligus and Lepeophtheirus.
  • an aquaculture parasiticidal kit comprising one or more containers containing spores of Bacillus thuringiensis subsp. Kurstaki strain ABTS-351 and/or ATCC-33679, and/or one or more recombinant proteins selected from CrylAb, Cry 1 Ac, Cry2 and Cry4, preferably with a veterinarily acceptable carrier, and an instruction for use insert.
  • the results of the claimed invention are different from the knowledge previously existing in the prior art in relation to the required dose, formulation thereof, the medium where it is used (seawater), the directions for use, and the organism to be controlled.
  • the formulation developed in the claimed invention contains Bt spores or recombinant Cry proteins or a combination of both. It is soluble (or homogenizable) in seawater. It is administered through different routes, including immersion baths. It is applied to control parasites (both copepodites and adults) of Caligus in fish, all of which is not derived in an obvious manner from the prior art.
  • Example 1 In vitro antiparasitic activity of Bacillus thuringiensis spores against Caligus rogercresseyi. 1.1. Effect of Bt spores on the survival of copepodites
  • Bacillus thuringiensis Bacillus thuringiensis (Bt) spores against caligus in larval stages (copepodites)
  • the strains used correspond to Bacillus thuringiensis subsp. Kurstaki strain ABTS-351, SA-11, strain ATCC-33679, and to a mixture of three Chilean native strains of Bacillus thuringiensis (N1-N2-N3) ( Figures 1 and 2).
  • B. thuringiensis strain ATCC-33679 was used to assess the effect thereof on adult caligus as compared to spores from the strains ABTS-351.
  • the antiparasitic effect of the spores of Bt strain ATCC-33679 on adult caligus was analyzed. For this purpose, 10 motile adult parasites were placed in Petri dishes, in a final volume of 1.5 mL of seawater.
  • the spores of Bt strain ATCC- 33679 were used at a dose of 2xl0 9 CFU/mL, as compared to the same dose of spores of strain ABTS-351 obtained under the same conditions. Each assay was carried out in duplicate.
  • Figure 2 shows the caligus survival results, wherein it is observed that spores of strain ATCC-33679 and the spores of strain ABTS-351 reach between 30% and 40% mortality of adult caligus in 300 minutes. Therefore, it is suggested that the spores of strain ATCC-33679 have an antiparasitic activity similar to that of the spores of strain ABTS-351, when comparing the spores produced under the same laboratory conditions.
  • the bacteria were grown in LB liquid medium and then their sporulation was induced in T3 medium (Peptone lOgr/Lt, NaCl 5gr/Lt, Glucose 34gr/Lt, yeast extract 20gr/Lt, MnCF 20mg/Lt) for 5 days at 28°C under stirring (200 rpm).
  • T3 medium Peptone lOgr/Lt, NaCl 5gr/Lt, Glucose 34gr/Lt, yeast extract 20gr/Lt, MnCF 20mg/Lt
  • the cultures were centrifuged at 5000 rpm for 30 minutes at 4°C, and the supernatant was removed, the spores were resuspended in 15 mL of sterile water, frozen at -80°C and then were subjected to lyophilization for 24 hours.
  • a yield of 1.85xl0 9 CFU/g of spores was obtained.
  • the culture medium used contains Peptone lOgr/Lt, NaCl 5gr/Lt, Glucose 34gr/Lt, yeast extract 20gr/Lt, nCF 20mg/L, and ZnCF 40mg/L. It was seeded with 20% pre inoculum and incubated for 8 days at 28°C.
  • the resulting spores of Bt strain ABTS-351 were freeze-dried and used in in vitro bioassays at a dose of 2xl0 8 CFU/mL against adult caligus and against larval stages of the parasite.
  • Figure 3 shows the survival of adult caligus, treated with Bt spores produced under the optimized experimental conditions. It was observed that these spores cause 100% mortality of adult caligus at a dose of 2xl0 8 CFU/mL. Therefore, when the sporulation yield and production of Cry crystals in the spores was optimized, a better caligus killing activity in adults was obtained, which allowed reducing between 10 and 100 times the active dose. Similar results were obtained by treating caligus larvae (copepodites) with the spores obtained in bioreactor.
  • Figure 4 shows the survival of copepodites treated with Bt spores produced under optimized fermentation conditions. It was observed that with a dose of 2.8x10 s CFU/mL, spores cause 100% mortality of larvae in 180 minutes, while in 60% of treatment more than 60% mortality is achieved.
  • Example 2 In vitro antiparasitic activity of recombinant Cry proteins against C. rogercresseyi
  • Cry proteins present in B. thuringiensis subs. Kurstaki were selected to obtain them in recombinant systems that overexpress proteins.
  • pET21b expression vectors were synthesized with the gene sequence of different Cry proteins.
  • the gene sequences encoding for proteins Cryl (CrylAb and Cry 1 Ac), Cry2 (Cry2Ad), Cry 3, and Cry4 were selected, which were inserted into the multiclonation site between the Ndel and Xhol restriction sites.
  • E. coli BL21 (DE3) cells were transformed, wherein protein expression was induced with IPTG, and were purified by affinity chromatography of the histidine tag present in the recombinant peptide, using a Ni-NTA agarose column.
  • the proteins were solubilized in an alkaline buffer (0.05M NaiCC , 0.005M b-mercaptoethanol, pH 10).
  • the Cry (CrylAb, CrylAc, Cry2Ad, Cry3, and Cry4) proteins were obtained from inclusion bodies or insoluble moiety of E. coli, after homogenizing and breaking open the cells by sonication, they were centrifuged and the pellet was treated with a basic solution at a pH of 10 (50 mM Na 2 C0 3 , 5 mM b-mercaptoethanol) and then resuspended under constant stirring at 37°C for 2 hours. Once resuspended, the pellet was centrifuged in a Sorvall centrifuge at 6000 rpm for 1 hour using a SS-34 rotor (4300 G) to obtain the proteins from the supernatant.
  • a basic solution at a pH of 10 50 mM Na 2 C0 3 , 5 mM b-mercaptoethanol
  • the proteins were purified by affinity chromatography, using a Ni-NTA agarose resin and imidazole 50 mM and 300 mM to elute the protein moieties.
  • the moieties containing the protein of interest were quantified according to the Bradford method and analyzed by 10% SDS-PAGE.
  • Figure 5 shows the elution profile of the protein CrylAb (130 kDa).
  • the protein elutes with 50 mM imidazole, as observed in moieties 1-1 and 1-2, reaching a purity between 82.9% and 85.1%.
  • the experimental yield for CrylAb was 0.6 mg of protein/gram of bacterial pellet.
  • the B. thuringiensis CrylAb protein was expressed in Hansenula polymorpha yeast using the pFPMT-M-CRYlA-6his plasmid to transform the strain RB11. These transformed yeasts showed an intracellular accumulation of CrylA, reaching comparatively high levels of up to ⁇ 30% of the total cell protein.
  • yeasts were subjected to fermentation in order to produce biomass of the strain Hansenula polymorpha RBll/pFPMT-M-CrylA-6his, which produces intracellular Bacillus thuringiensis CrylAb.
  • an optical density at 600 nm of about 330 OD was reached, corresponding to a biomass yield of 94 g dcw/F (dew: dry celular weight).
  • the yeast was grown in YP/YNB culture broth with glycerol (20 g/1 yeast extract, 40 g/1 soybean peptone, 3.4 g/1 YNB without ammonium sulfate, 10 g/1 (NH 4 ) 2 S0 4 , 30 g/1 glycerol, pH 6), and a cell paste (dew) was collected by decantation. With the cell paste a cell disruption mechanical method was standardized to break open the yeast cells and obtain an extract of soluble proteins, which contained about 25% of recombinant CrylAb, relative to the total protein content of the extract.
  • an alkaline buffer 50 mM sodium carbonate pH 10, 5 mM b-mercaptoethanol, 10% glycerol, and protease inhibitors.
  • the total protein yield for the protein extracts was 50.53 mg of total protein/g of cell paste.
  • the protein was purified, which contained a histidine tag (about 5 mg total protein/mL), from a 10 mL aliquot of protein extract supernatant, by means of an affinity chromatography using a Ni-NTA agarose resin in alkaline buffer.
  • the protein moieties were collected by imidazole washings (50-300 mM).
  • Figure 6 shows the purification results of CrylAb from Hansenula polymorpha. The protein elutes with 50 mM imidazole, as observed for the moieties 1-2 and 1-3, and 300 mM imidazole in the moieties 2-1 and 2-2.
  • the treatment of larvae was carried out using 300 pg/mL of CrylAb, Cry2 and Cry3 proteins. With CrylAb protein in 300 minutes of treatment 100% larval mortality was obtained (Figure 7). When the larvae were treated with Cry2 protein, about 90% mortality was obtained in 300 minutes, while the larvae treated with Cry 3 protein showed no mortality.
  • Cry A proteins CrylAb and Cryl Ac produced in E. coli BL21 and CrylAb produced in H. polymorpha
  • 10 adult caligus were placed in Petri dishes with seawater and treated with 150 pg/mL of each CrylA protein.
  • Figure 12A shows that both recombinant CrylAb proteins have control over Caligus, regardless of their origin (prokaryotes or eukaryotes), with a range between 60-80% mortality of the parasite.
  • Figure 12B shows that the CrylAb protein is more active against the parasites than Cry 1 Ac.
  • Example 3 In vitro antiparasitic effect of combinations of the CrylAb protein with other recombinant Cry proteins and with B. thuringiensis spores, against C. rogercresseyi.
  • Figure 15 shows the effect on adult caligus of the Bt strain ABTS-351 spore formulation (dose lxlO 8 CFU/mL) combined with the CrylAb protein produced in E. coli in different doses. It is observed that with the formulation of spores and CrylAb protein 100% mortality is caused in a lower time than with spores or Cry protein on their own.
  • the formulation of spores lxlO 8 CFU/mL) and CrylAb causes more than 70% mortality of adult caligus in 30 minutes of treatment, and 100% mortality in 90 minutes.
  • Figure 16 shows the effect on copepodites of supplementation of Bt strain ABTS-351 spores with the CrylAb protein, produced in E. coli.
  • the spore formulation dose of lxlO 8 CFU/mL
  • 150 pg/mL of CrylAb cause about 80% mortality in 60 minutes of treatment, while spores on their own cause less than 30% mortality in the same time of exposure.
  • the formulation of spores and CrylAb protein causes 100% mortality of caligus.
  • the synergistic effect proven in the claimed invention is a surprising technical effect of the combination, which cannot be attributed or derived from the separate effects of the spores or the CrylAb protein.
  • Colby's method is based on a mathematical formula that allow predicting the expected response from a combination of herbicides. This formula is as follows:
  • this equation allows predicting the expected survival value for the combination of two components of a formulation. If the expected survival value is greater than the observed experimental value, this means that there is synergy between the components; on the contrary, when the expected survival value is lower than the one observed, then antagonism is observed.
  • the expected survival value of caligus treated with a combination of spores at a dose of lxlO 8 CFU/mL and CrylAb protein at a concentration of 150 pg/mL was considered.
  • the survival percentages of adult caligus were assessed in 60 and 90 minutes of treatment, using an average of 5 replicates of in vitro treatments. For example, when the equation is replaced with the survival values in 90 minutes for CrylAb and spores, the following is obtained: i 100 100 33.03 % exp r ected survival
  • the expected survival percentage is 33.03%, this value is higher (almost double) than the one observed experimentally (16%); therefore, it is demonstrated that the formulation of spores with CrylAb has a synergistic effect against adult caligus.
  • a similar result of synergy can be observed in 60 minutes of treatment.
  • the results obtained in 60 and 90 minutes are shown in Table 3.
  • the protein overexpression system in Hansenula polymorpha was used.
  • the yeasts were fermented, obtaining a protein extract containing a total of 55.56 g of protein.
  • the resulting protein extract contains 30% of the recombinant CrylAb protein according to the estimations based on the polyacrylamide gel analysis using the Gel Pro Analyzer program, version 3.1.
  • the in vivo assay was performed to determine the antiparasitic activity of spores, and spores combined with protein extract containing CrylAb on adult caligus attached to the fish.
  • the fish S . salar, about 300 g were subjected to an immersion treatment with Bt strain ABTS- 351 spores at a dose of lxlO 8 CFU/mL, in 500 L tanks, and they were compared to control fish that received an immersion treatment only with seawater.
  • Table 4 Results of the antiparasitic bath of fish with Bt strain ABTS-351 spores, under controlled conditions.
  • Figure 18 shows the survival percentages of caligus attached to the fish, after the immersion treatment with spores. A 27% decrease in the parasitic load of fish treated with Bt spores was obtained after 60 minutes of treatment, a similar result to the one observed in vitro with spores produced under the same conditions.
  • fish of the Salmo salar species were used, weighting about 350 g, maintained in 500 L tanks (30 fish per tank), infested with a high load of Caligus rogercresseyi (47.4 caligus/fish).
  • the fish were subjected to an immersion (bath) treatment for 60 minutes, reducing the volume of the tanks to 120 L, with the formulation of Bt strain ABTS-351 spores at a dose of lxlO 9 CFU/mL combined with CrylAb produced in Hansenula polymorpha, without purification (protein extract at a concentration of 420 pg/mL).
  • the antiparasitic effect of the formulation was compared to a control tank, wherein the tank volume was reduced to 100 L, and then seawater was gradually added for about 5 minutes, to complete 120 L, and the fish were maintained there for 60 minutes. Once the immersion treatments were finished, about 60 minutes after, the total tank volume (500 L) was completed and after 2 hours of recovery, 15 fish were sampled from each tank to count the parasites attached.
  • Table 5 shows a summary of the results obtained after the treatment of infested fish with a high parasitic load of Caligus rogercresseyi , with the formulation of Bt spores supplemented with the protein extract (420 pg/mL), containing 30% of CrylAb, equivalent to about 126 pg/mL of CrylAb protein.
  • Table 5 Results of the antiparasitic bath in parasitized S. solar fish with Bt spores combined with CrylAb proteins (420 pg/mL), under controlled conditions.
  • Figure 19 shows the survival percentage of caligus attached per fish after treatment with the formulation of Bt strain ABTS-351 spores supplemented with protein extracts containing CrylAb without purification, compared to the survival percentage of caligus from the control tank. It was observed that the control has a caligus loss due to manipulation of about 10%, while the treatment with the formulation of spores and protein extract causes almost 38% mortality of caligus. This result is similar to the one observed in vitro with spores and proteins produced under the same conditions (see Figure 19B).
  • the Cry protein toxicity assessment assay was carried out by injecting 300 pg of CrylAb (Test 1) and 300 pg of Cry Ac (Test 2) (contained in a 100 pL injection volume), which corresponds to a dose of about 150 pg/mL in the serum of 30 g fish ( S . salar).
  • 10 fish were injected with 100 pL alkaline buffer (buffer where CryAb is resuspended) (Cl) and 10 fish were injected with 100 pL Tris buffer (buffer where CrylAc is resuspended) (C2).
  • the injected fish were kept under observation for 15 days.
  • Example 7 In vivo antiparasitic effect of CrylAb, administered by injection to salmons
  • this test assessed the efficacy against C. rogercresseyi, of the CrylAb protein produced in E. coli, in an injectable formulation.
  • the CrylAb protein was administered by injection to 4 Atlantic salmon post-smolts weighting about 120 g, infested with caligus. Each fish received a 130 pL injection of a 9.3 mg/mL solution of CrylAb purified from E. coli (1.2 mg CrylAb were injected per fish) and its effect was compared to 4 control fish, which were injected with the same volume of physiological serum (0.9% NaCl). The fish were kept at 12°C ⁇ 1°C, with 70% oxygen saturation. Prior to the injection, the fish were infested with an average of about 35-45 larvae (copepodites) per fish.
  • the injection was applied when most of the lice were in the developmental Chalimus stage, and twelve (12) days after the injection, the antiparasitic efficacy of injectable CrylAb was assessed, by counting the sea lice attached to the fish, in Chalimus and mobile adult stages.
  • the fish were anesthetized with benzocaine and the number of caligus attached to the fish was registered, as well as those arranged in the sampling container.
  • the measurement of the antiparasitic effect of Cry 1 Ab in an injectable formulation was determined in terms of the counting of mobile lice (adult) and chalimus attached to each fish post treatment.
  • Example 8 In vitro antiparasitic effect of combinations of CrylAb protein and B. thuringiensis spores against Lepeophtheirus salmonis (L. salmonis).
  • the in vitro antiparasitic activity of the complementation of spores of Bt strain ABTS-351 was determined in different doses: lxlO 7 , lxlO 8 , lxlO 9 and lxlO 10 CFU/mL, with the CrylAb protein purified from E. coli, in the following doses: 25 pg/mL, 75 pg/mL and 150 pg/mL, as compared to the effect observed with CrylAb and spores alone.
  • 10 specimens of adult L. salmonis were used per plate, in a final volume of 2 mL of sea water.

Abstract

La présente invention concerne le développement d'une formulation ou d'une composition antiparasitaire à base de spores de Bacillus thuringiensis et/ou de protéines Cry recombinantes de la même bactérie, administrés ensemble ou chacun séparément, pour le traitement de l'infection provoquée par des parasites (poux de mer) de la famille des Caligidae chez les poissons. De plus, le développement comprend un procédé de traitement d'une infestation de poux de mer, ladite composition antiparasitaire étant administrée chez les poissons. Les spores sont produites dans des conditions de fermentation optimisées et des protéines Cry obtenues à partir de systèmes d'expression procaryotes ou eucaryotes.
EP20756975.7A 2019-08-09 2020-08-10 Formulation antiparasitaire de spores et/ou de protéines de bacillus thuringiensis pour le traitement de parasites de la familledes caligidae chez les poissons Pending EP4009794A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885034P 2019-08-09 2019-08-09
PCT/IB2020/057511 WO2021028817A1 (fr) 2019-08-09 2020-08-10 FORMULATION ANTIPARASITAIRE DE SPORES ET/OU DE PROTÉINES DE BACILLUS THURINGIENSIS POUR LE TRAITEMENT DE PARASITES DE LA FAMILLE<i />DES CALIGIDAE CHEZ LES POISSONS

Publications (1)

Publication Number Publication Date
EP4009794A1 true EP4009794A1 (fr) 2022-06-15

Family

ID=72086936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20756975.7A Pending EP4009794A1 (fr) 2019-08-09 2020-08-10 Formulation antiparasitaire de spores et/ou de protéines de bacillus thuringiensis pour le traitement de parasites de la familledes caligidae chez les poissons

Country Status (3)

Country Link
EP (1) EP4009794A1 (fr)
DK (1) DK202270092A1 (fr)
WO (1) WO2021028817A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588849B2 (en) 1985-01-17 1989-09-28 Microbial Products Pty Ltd Microbial control of louse populations
US5273746A (en) 1992-01-29 1993-12-28 Mycogen Corporation Bacillus thuringiensis isolates active against phthiraptera pests
GB2371053A (en) * 2001-01-13 2002-07-17 David R Harper Microbiological control of sea lice
US20040047840A1 (en) 2001-01-13 2004-03-11 David Harper Control agents
JP3659419B1 (ja) 2004-06-04 2005-06-15 株式会社九州メディカル バチルス・チューリンジェンシスを有効成分とする水産魚介類病原カビに対する防除剤
JP2008533054A (ja) 2005-03-14 2008-08-21 マイクロビアル プロダクツ プロプライエタリー リミテッド 吸血シラミの駆除
WO2009052242A2 (fr) * 2007-10-16 2009-04-23 Athenix Corporation Axmi-066 et axmi-076 : protéines de delta-endotoxine et leurs procédés d'utilisation
US8735560B1 (en) * 2010-03-02 2014-05-27 Monsanto Technology Llc Multiple domain lepidopteran active toxin proteins
US9205116B2 (en) 2011-04-29 2015-12-08 Auburn University Bacillus bacteria for use in treating and preventing infection in aquatic animals
NZ727213A (en) * 2012-03-09 2020-03-27 Vestaron Corp Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
CN104397034A (zh) 2014-11-12 2015-03-11 苏州市相城区盛胡特种养殖专业合作社 一种环保型水产用杀虫剂及其制备方法
US20180127771A1 (en) * 2016-11-10 2018-05-10 Iowa State University Research Foundation, Inc. Insecticidal toxins for plant resistance to hemiptera

Also Published As

Publication number Publication date
DK202270092A1 (en) 2022-05-11
WO2021028817A1 (fr) 2021-02-18

Similar Documents

Publication Publication Date Title
McNair Ectoparasites of medical and veterinary importance: drug resistance and the need for alternative control methods
Moreau “It stings a bit but it cleans well”: Venoms of Hymenoptera and their antimicrobial potential
Pu et al. An entomopathogenic bacterium strain, Bacillus thuringiensis, as a biological control agent against the red palm weevil, Rhynchophorus ferrugineus (Coleoptera: Curculionidae)
JPH0383576A (ja) 生物製剤の封入法
BELARMINO Nematicidal Activity of Bacillus spp. Strains on Juveniles of Meloidogyne javanica.
Lohmeyer et al. Pathogenicity of three formulations of entomopathogenic fungi for control of adult Haematobia irritans (Diptera: Muscidae)
Luiz Rosa da Silva et al. Larvicidal and growth-inhibitory activity of entomopathogenic bacteria culture fluids against Aedes aegypti (Diptera: Culicidae)
Liu et al. Isolation and characterization of Pseudomonas cedrina infecting Plutella xylostella (Lepidoptera: Plutellidae)
Pereira et al. Bioactivity under laboratory conditions of Brevibacillus laterosporus towards larvae and adults of Chrysomya putoria (Diptera: Calliphoridae)
Mehrabi et al. A study of the effect of Bacillus thuringiensis serotype H14 (subspecies israelensis) delta endotoxin on Musca larva
Yadav et al. Tick saliva toxins, host immune responses and its biological effects
WO2021028817A1 (fr) FORMULATION ANTIPARASITAIRE DE SPORES ET/OU DE PROTÉINES DE BACILLUS THURINGIENSIS POUR LE TRAITEMENT DE PARASITES DE LA FAMILLE&lt;i /&gt;DES CALIGIDAE CHEZ LES POISSONS
JP2008533054A (ja) 吸血シラミの駆除
Shaik et al. Competitive interactions between entomopathogenic nematodes and parasitoid venom
Etim In vitro evaluation of Bacillus thuringiensis larvicide effect on Anopheles subpictus larvae.
Leathwick et al. Biocontrol of sheep blowfly: is there a role for pathogen-based biopesticides?
US20220249577A1 (en) Methods and compositions for controlling or reducing pests
Dewi et al. Isolation of entomopathogenic Lysinibacillus sphaericus from sewage at some housing complex in Mataram city and evaluation of its toxicity against Aedes aegypti larvae in laboratory
Sanders The anthelmintic effect of Bacillus thuringiensis Cry5B on Haemonchus contortus in sheep
Baran A mini-review of Bacillus thuringiensis application to control important economic and zoonotic parasites.
Baran Journal of Zoonotic Diseases
Kumawat et al. An approach to sustainable control of mosquitoes.
Norashiqin Misni et al. Larvicidal effect of Trypsin Modulating Oostatic Factor (TMOF) formulations on Aedes aegypti larvae in the laboratory.
Rahman et al. Characterization of Bacillus spharicus binary proteins for biological control of Culex quinquefasciatus mosquitoes: a review.
Zeeshan et al. In vitro comparative acaricidal efficacy of ivermectin and Metarhizium anisopliae (Hypocreales: Clavicipitaceae) against adult Hyalomma anatolicum ticks (Acari: Ixodidae).

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)